Real-world efficacy and safety of first-line nivolumab plus chemotherapy in patients with advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: A nationwide observational Turkish Oncology Group (TOG) study

Basit Öğe Kaydı
dc.authorid0000-0003-2184-634X
dc.authorid0000-0003-2538-8569
dc.authorid0000-0001-7934-7039
dc.authorid0000-0002-0443-6966
dc.contributor.authorKutlu, Yasin
dc.contributor.authorDae, Shute Ailia
dc.contributor.authorYılmaz, Feride
dc.contributor.authorErdem, Dilek
dc.contributor.authorŞendur, Mehmet Ali Nahit
dc.contributor.authorAkbaş, Sinem
dc.contributor.authorŞenocak Taşçı, Elif
dc.contributor.authorBaş, Onur
dc.contributor.authorDane, Faysal
dc.contributor.authorSakin, Abdullah
dc.contributor.authorKaya, Ali Osman
dc.contributor.authorAykan, Musa Barış
dc.contributor.authorErgün, Yakup
dc.contributor.authorBiter, Sedat
dc.contributor.authorDişel, Umut
dc.contributor.authorKorkmaz, Mustafa
dc.contributor.authorSelçukbiricik, Fatih
dc.contributor.authorKöse, Fatih
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorBilici, Ahmet
dc.contributor.authorDemir, Gökhan
dc.contributor.authorYalçın, Şuayib
dc.date.accessioned2024-07-09T09:41:53Z
dc.date.available2024-07-09T09:41:53Z
dc.date.issued2024
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractBased on the CheckMate 649 trial, nivolumab plus chemotherapy is the recommended first-line treatment for HER2-negative unresectable advanced or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma. This nationwide, multicenter, retrospective study evaluated the real-world effectiveness of this regimen in Turkish patients and identified subgroups that may experience superior outcomes. Conducted across 16 oncology centers in Turkey, this study retrospectively reviewed the clinical charts of adult patients diagnosed with HER2-negative unresectable advanced or metastatic gastric, GEJ, or esophageal adenocarcinoma from 2016 to 2023. This study included 111 patients (54 women, 57 men) with a median age of 58 years. The median progression-free survival (PFS) and overall survival (OS) were 11.7 months and 18.2 months, respectively, whereas the objective response rate (ORR) was 70.3%. Multivariable analyses revealed that previous curative surgery was a favorable independent prognostic factor for both PFS and OS. Conversely, an Eastern Cooperative Oncology Group performance status of 2 emerged as an adverse independent prognostic factor for OS. The safety profile of nivolumab plus chemotherapy was found to be manageable. Our findings support the use of nivolumab plus chemotherapy for the first-line treatment of Turkish patients with HER2-negative unresectable advanced or metastatic gastric, GEJ, or esophageal adenocarcinoma. Patient selection based on clinical characteristics is crucial for optimizing treatment outcomes.
dc.identifier.citationKutlu, Y., Dae, S. A., Yılmaz, F., Erdem, D., Şendur, M. A. N., Akbaş, S. ... Yalçın, Ş. (2024). Real-world efficacy and safety of first-line nivolumab plus chemotherapy in patients with advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: A nationwide observational Turkish Oncology Group (TOG) study. Cancers, 16(12). http://dx.doi.org/10.3390/cancers16122251
dc.identifier.doi10.3390/cancers16122251
dc.identifier.issn2072-6694
dc.identifier.issue12
dc.identifier.pmid38927957
dc.identifier.scopus2-s2.0-85197150456
dc.identifier.scopusqualityQ1
dc.identifier.urihttp://dx.doi.org/10.3390/cancers16122251
dc.identifier.urihttps://hdl.handle.net/20.500.12511/12709
dc.identifier.volume16
dc.identifier.wos001254635300001en_US
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKutlu, Yasin
dc.institutionauthorSakin, Abdullah
dc.institutionauthorÖlmez, Ömer Fatih
dc.institutionauthorBilici, Ahmet
dc.language.isoen
dc.relation.ispartofCancersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution 4.0 International*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subjectChemotherapy
dc.subjectEfficacy
dc.subjectGastric Adenocarcinoma
dc.subjectNivolumab
dc.subjectReal-World
dc.subjectSafety
dc.titleReal-world efficacy and safety of first-line nivolumab plus chemotherapy in patients with advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: A nationwide observational Turkish Oncology Group (TOG) study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Kutlu-Yasin-2024.pdf
Boyut:
629.86 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu